Fate Execs Sued After $50M Deal With J&J Unit Falls Apart

By Katryna Perera · June 6, 2023, 5:47 PM EDT

Executives of biopharmaceutical company Fate Therapeutics Inc. have been hit with a shareholder derivative suit alleging they misled investors about the feasibility of a $50 million collaboration agreement with a Johnson...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Guarino v. Wolchko et al

Case Number

3:23-cv-01033

Court

California Southern

Nature of Suit

Securities/Commodities

Date Filed

June 02, 2023